Drug Interaction Vectors Neural Network: DrIVeNN

• URL: http://arxiv.org/abs/2308.13891v1
• Date: Sat, 26 Aug 2023 14:24:41 GMT
• Title: Drug Interaction Vectors Neural Network: DrIVeNN
• Authors: Natalie Wang, Casey Overby Taylor
• Abstract summary: Polypharmacy is the concurrent use of multiple drugs to treat a single condition. Many serious ADEs associated with polypharmacy only become known after the drugs are in use. It is impractical to test every possible drug combination during clinical trials.
• Score: 0.7624669864625037
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: Polypharmacy, the concurrent use of multiple drugs to treat a single condition, is common in patients managing multiple or complex conditions. However, as more drugs are added to the treatment plan, the risk of adverse drug events (ADEs) rises rapidly. Many serious ADEs associated with polypharmacy only become known after the drugs are in use. It is impractical to test every possible drug combination during clinical trials. This issue is particularly prevalent among older adults with cardiovascular disease (CVD) where polypharmacy and ADEs are commonly observed. In this research, our primary objective was to identify key drug features to build and evaluate a model for modeling polypharmacy ADEs. Our secondary objective was to assess our model on a domain-specific case study. We developed a two-layer neural network that incorporated drug features such as molecular structure, drug-protein interactions, and mono drug side effects (DrIVeNN). We assessed DrIVeNN using publicly available side effect databases and determined Principal Component Analysis (PCA) with a variance threshold of 0.95 as the most effective feature selection method. DrIVeNN performed moderately better than state-of-the-art models like RESCAL, DEDICOM, DeepWalk, Decagon, DeepDDI, KGDDI, and KGNN in terms of AUROC for the drug-drug interaction prediction task. We also conducted a domain-specific case study centered on the treatment of cardiovascular disease (CVD). When the best performing model architecture was applied to the CVD treatment cohort, there was a significant increase in performance from the general model. We observed an average AUROC for CVD drug pair prediction increasing from 0.826 (general model) to 0.975 (CVD specific model). Our findings indicate the strong potential of domain-specific models for improving the accuracy of drug-drug interaction predictions.

Related papers

• drGAT: Attention-Guided Gene Assessment of Drug Response Utilizing a Drug-Cell-Gene Heterogeneous Network [9.637695046701493]
  drGAT is a graph deep learning model that can predict sensitivity to drugs. drGAT has superior performance over existing models, achieving 78% accuracy and 76% F1 score for 269 DNA-damaging compounds. Our method can be used to accurately predict sensitivity to drugs and may be useful in the identification of biomarkers relating to the treatment of cancer patients.
  arXiv  Detail & Related papers  (2024-05-14T22:16:52Z)
• CT-ADE: An Evaluation Benchmark for Adverse Drug Event Prediction from Clinical Trial Results [0.10051474951635876]
  Adverse drug events (ADEs) significantly impact clinical research, causing many clinical trial failures. To support this effort, we introduce CT-ADE, a dataset for multilabel predictive modeling of ADEs in monopharmacy treatments. CT-ADE integrates data from 2,497 unique drugs, encompassing 168,984 drug-ADE pairs extracted from clinical trials, annotated with patient and contextual information, and comprehensive ADE concepts standardized across multiple levels of the MedDRA.
  arXiv  Detail & Related papers  (2024-04-19T12:04:32Z)
• Enhancing Acute Kidney Injury Prediction through Integration of Drug Features in Intensive Care Units [0.0]
  The relationship between acute kidney injury (AKI) prediction and nephrotoxic drugs has yet to be explored in the critical care setting. This study proposes a novel approach that leverages patient prescription data as a modality to improve existing models for AKI prediction.
  arXiv  Detail & Related papers  (2024-01-09T05:42:32Z)
• Emerging Drug Interaction Prediction Enabled by Flow-based Graph Neural Network with Biomedical Network [69.16939798838159]
  We propose EmerGNN, a graph neural network (GNN) that can effectively predict interactions for emerging drugs. EmerGNN learns pairwise representations of drugs by extracting the paths between drug pairs, propagating information from one drug to the other, and incorporating the relevant biomedical concepts on the paths. Overall, EmerGNN has higher accuracy than existing approaches in predicting interactions for emerging drugs and can identify the most relevant information on the biomedical network.
  arXiv  Detail & Related papers  (2023-11-15T06:34:00Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Neural Bandits for Data Mining: Searching for Dangerous Polypharmacy [63.135687276599114]
  Some polypharmacies, deemed inappropriate, may be associated with adverse health outcomes such as death or hospitalization. We propose the OptimNeuralTS strategy to efficiently mine claims datasets and build a predictive model of the association between drug combinations and health outcomes. Our method can detect up to 72% of PIPs while maintaining an average precision score of 99% using 30 000 time steps.
  arXiv  Detail & Related papers  (2022-12-10T03:43:23Z)
• DDI Prediction via Heterogeneous Graph Attention Networks [0.0]
  Polypharmacy is the use of multiple drugs together. Drug-drug interaction (DDI) is the activity that occurs when the impact of one drug changes when combined with another. We present a novel heterogeneous graph attention model, HAN-DDI, to predict drug-drug interactions.
  arXiv  Detail & Related papers  (2022-07-12T16:59:06Z)
• HyGNN: Drug-Drug Interaction Prediction via Hypergraph Neural Network [0.0]
  Drug-Drug Interactions (DDIs) may hamper the functionalities of drugs, and in the worst scenario, they may lead to adverse drug reactions (ADRs) This paper proposes a novel Hypergraph Neural Network (HyGNN) model based on only the SMILES string of drugs, available for any drug, for the DDI prediction problem. Our proposed HyGNN model effectively predicts DDIs and impressively outperforms the baselines with a maximum ROC-AUC and PR-AUC of 97.9% and 98.1%, respectively.
  arXiv  Detail & Related papers  (2022-06-25T22:48:27Z)
• Multi-View Substructure Learning for Drug-Drug Interaction Prediction [69.34322811160912]
  We propose a novel multi- view drug substructure network for DDI prediction (MSN-DDI) MSN-DDI learns chemical substructures from both the representations of the single drug (intra-view) and the drug pair (inter-view) simultaneously and utilizes the substructures to update the drug representation iteratively. Comprehensive evaluations demonstrate that MSN-DDI has almost solved DDI prediction for existing drugs by achieving a relatively improved accuracy of 19.32% and an over 99% accuracy under the transductive setting.
  arXiv  Detail & Related papers  (2022-03-28T05:44:29Z)
• SafeDrug: Dual Molecular Graph Encoders for Safe Drug Recommendations [59.590084937600764]
  We propose a DDI-controllable drug recommendation model named SafeDrug to leverage drugs' molecule structures and model DDIs explicitly. On a benchmark dataset, our SafeDrug is relatively shown to reduce DDI by 19.43% and improves 2.88% on Jaccard similarity between recommended and actually prescribed drug combinations over previous approaches.
  arXiv  Detail & Related papers  (2021-05-05T00:20:48Z)
• HINT: Hierarchical Interaction Network for Trial Outcome Prediction Leveraging Web Data [56.53715632642495]
  Clinical trials face uncertain outcomes due to issues with efficacy, safety, or problems with patient recruitment. In this paper, we propose Hierarchical INteraction Network (HINT) for more general, clinical trial outcome predictions.
  arXiv  Detail & Related papers  (2021-02-08T15:09:07Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.